Want to see MDGL full AI Analyst Report?
MDGL Stock Chart & Stats
$512.16
$10.45(1.92%)
At close: 4:00 PM EDT
$512.16
$10.45(1.92%)
Day’s Range― - ―
52-Week Range$393.61 - $615.00
Previous CloseN/A
Volume138.02K
Average Volume (3M)368.81K
Market Cap
$12.33B
Enterprise Value$15.16K
Total Cash (Recent Filing)$838.75M
Total Debt (Recent Filing)$347.75M
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Oct 29, 2026EPS Estimate
-0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.89
Shares Outstanding23,104,126
10 Day Avg. Volume262,543
30 Day Avg. Volume368,805
Financial Highlights & Ratios
PEG Ratio1.10
Price to Book (P/B)21.68
Price to Sales (P/S)13.63
P/FCF Ratio-68.75
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$689.08Price Target Upside34.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-6.26
Revenue Forecast (FY)$1.52B
Bulls Say, Bears Say
Bulls Say
Rapid Commercialization And High Gross MarginsRevenue increased sharply while gross margins remained exceptionally high, indicating strong Rezdiffra adoption and attractive product economics. This creates a substantial commercial foundation and could support operating leverage as the business scales.
Positive Equity And Substantial Asset BasePositive equity and a sizable asset base provide financial support for ongoing commercialization and pipeline activities. This balance-sheet cushion improves execution capacity over the medium term, although it does not remove the need to reduce losses and cash consumption.
Strengthened Scientific And Strategic OversightAdding a prominent biopharma R&D leader can strengthen scientific oversight, global development expertise, and governance as Madrigal expands MASH commercialization. His committee role may improve long-term pipeline and innovation decision-making.
Bears Say
Persistent UnprofitabilityDespite rapid revenue growth and high gross margins, operating expenses remain too large for the current revenue base. Continued net, EBIT, and EBITDA losses show that commercialization has not yet translated into sustainable operating profitability.
Material And Worsening Cash BurnNegative operating and free cash flow means the company is still consuming cash while scaling its commercial platform. Persistent burn could increase reliance on external funding and constrain investment flexibility until operations reach cash-flow breakeven.
Rising Leverage And Negative Capital ReturnsHigher leverage reduces financial flexibility if losses persist, while deeply negative return on equity indicates capital is being consumed rather than generating returns. This raises execution risk during the company’s commercialization and expansion phase.
Madrigal Pharmaceuticals News
MDGL FAQ
What was Madrigal Pharmaceuticals Inc’s price range in the past 12 months?
Madrigal Pharmaceuticals Inc lowest stock price was $393.61 and its highest was $615.00 in the past 12 months.
What is Madrigal Pharmaceuticals Inc’s market cap?
Madrigal Pharmaceuticals Inc’s market cap is $12.33B.
When is Madrigal Pharmaceuticals Inc’s upcoming earnings report date?
Madrigal Pharmaceuticals Inc’s upcoming earnings report date is Oct 29, 2026 which is in 58 days.
How were Madrigal Pharmaceuticals Inc’s earnings last quarter?
Madrigal Pharmaceuticals Inc released its earnings results on Jul 30, 2026. The company reported -$1.99 earnings per share for the quarter, beating the consensus estimate of -$2.677 by $0.687.
Is Madrigal Pharmaceuticals Inc overvalued?
According to Wall Street analysts Madrigal Pharmaceuticals Inc’s price is currently Undervalued.
Does Madrigal Pharmaceuticals Inc pay dividends?
Madrigal Pharmaceuticals Inc does not currently pay dividends.
What is Madrigal Pharmaceuticals Inc’s EPS estimate?
Madrigal Pharmaceuticals Inc’s EPS estimate is -0.86.
How many shares outstanding does Madrigal Pharmaceuticals Inc have?
Madrigal Pharmaceuticals Inc has 23,104,126 shares outstanding.
What happened to Madrigal Pharmaceuticals Inc’s price movement after its last earnings report?
Madrigal Pharmaceuticals Inc reported an EPS of -$1.99 in its last earnings report, beating expectations of -$2.677. Following the earnings report the stock price went down -9.832%.
Which hedge fund is a major shareholder of Madrigal Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in MDGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Madrigal Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$689.08 (34.54% Upside)
$689.08 (34.54% Upside)
Blogger Sentiment
Bullish
MDGL Sentiment 71%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 89.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $341.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 7.4%
Last 30 Days ▼ 7.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
22.58%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
MDGL Company Deck
MDGL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive commercial and scientific momentum: Rezdiffra has achieved blockbuster status with rapid patient growth, a materially expanding addressable market, and an increasingly diverse pipeline (including a promising siRNA asset). These positives are balanced by elevated operating expenses, one‑time business development costs, a material gross‑to‑net discount, and near‑term non‑profitability with cash modestly reduced by strategic uses. Management emphasized durable long‑term opportunity, upcoming outcomes milestones (2027–2028), and disciplined, data‑driven pipeline advancement.View all MDGL earnings summariesMDGL Stock 12 Month Forecast
Average Price Target
$689.08
▲(34.54% Upside)
Technical Analysis
Exelixis
―
Ionis Pharmaceuticals
―
Ascendis Pharma
―
BridgeBio Pharma
―
Roivant Sciences
―
Ownership Overview
18.14% Insiders
25.13% Mutual Funds
6.70% Other Institutional Investors
37.91% Public Companies and
Individual Investors